

## **CONTENTS**

Analysis of somatic mutations involves separation of complex mixtures

Clone-by-clone mutational scanning: a tour de force approach in somatic mutation analysis

Post-PCR cloning: simplicity at the cost of PCR artifacts

Single-molecule PCR in mutational analysis: PCR without the artifacts

Expert commentary & five-year view

References

**Affiliations** 

† Author for correspondence Beth Israel Deaconess Medical Center & Harvard Medical School, 21–27 Burlington Avenue, Boston MA 02215, USA Tel.: PHONE Fax: FAX khrapko@hms.harvard.edu

## KEYWORDS:

aging, allelic preference, jumping PCR, mitochondrial DNA, mutational spectra, PCR errors, single-molecule PCR, somatic mutations, recombination

# Single-molecule PCR: an artifact-free PCR approach for the analysis of somatic mutations

Yevgenya Kraytsberg and Konstantin Khrapko<sup>†</sup>

A critical review of the clone-by-clone approach to the analysis of complex spectra of somatic mutations is presented. Studying of *a priori*, unknown, somatic mutations requires painstaking analysis of complex mixtures of multiple mutant and non-mutant DNA molecules. If mutant fractions are sufficiently high, these mixtures can be dissected by cloning of individual DNA molecules and scanning of the individual clones for mutations (e.g., by sequencing). Currently, the majority of such cloning is performed using PCR fragments. However, post-PCR cloning may result in various PCR artifacts – PCR errors and jumping PCR – and preferential amplification of certain mutations. This review argues that single-molecule PCR is a simple alternative that promises to evade the disadvantages inherent to post-PCR cloning and enhance mutational analysis in the future.

Expert Rev. Mol. Diagn. 5(5), xxx-xxx (2005)

Somatic mutations are responsible for developmental defects, cancer and possibly aging. To fully appreciate the abundance and impact of somatic mutations, and to study their sources, one needs to measure mutational spectra – the distributions of (*a priori* unknown) mutations present within a certain DNA fragment, by type and frequency.

## Analysis of somatic mutations involves separation of complex mixtures

Measuring somatic mutational spectra has always been a challenge, the two main problems being the low frequency of each individual mutation and the high complexity of mixtures of mutations that need to be analyzed. Although overall load of somatic mutations in the genome of a typical cell may be high, the probability of a mutation occuring within the relatively short fragment selected for analysis is usually quite low. Furthermore, a typical mutational spectrum, even for a short DNA fragment, consists of a large number of mutational hotspots of variable intensity [1]. As a result, when studying somatic mutations, one has to be prepared to deal with a complex mixture of a large number of wild-type molecules containing individually rare mutant molecules of multiple types.

Separation of complex wild-type/mutant mixtures is a difficult analytical problem. A few efficient separation methods, mostly based on differential melting of the wild type and the various mutant DNA molecules, have been used for this purpose. However efficient these approaches are, they do not guarantee that all mutations are detected. Furthermore, once mutants are separated from the wild type and from each other, they still need to be further purified for identification of mutations by sequencing. This last purification step is sometimes quite laborious, while separation itself requires either expensive equipment or a lot of skillful effort.

Clone-by-clone mutational scanning: a tour de force approach in somatic mutation analysis

Alternatively, a complex mixture of mutations can be analyzed in the molecule-by-molecule mode. In this approach, a large number of molecules from the mixture are cloned, and each molecule is scanned for the presence of a mutation(s), for example, by sequencing in the case of point mutations. The distribution of mutations in the original sample is then approximated by the distribution of mutations among

www.future-drugs.com 10.1586/14737159.5.5.xxx © 2005 Future Drugs Ltd ISSN 1473-7159 **1** 

molecules sampled by the cloning procedure [2]. This is a simple straightforward approach where one's ability to detect mutations is limited by the number of clones that can be analyzed. As the cost of DNA sequencing continues to decrease and the high-throughput format becomes routinely available in molecular biology laboratories, the clone-by-clone approach becomes highly competitive. The approach is especially suitable for hypermutable regions of the genome, where the expected fraction of mutant clones is relatively high and thus not too much effort is spent on nonproductive sequencing of the wild-type DNA.

Mitochondrial DNA (mtDNA) is in fact one of the most hypermutable components of the genome. Somatic mutant rates in mtDNA may be approximately 3 orders of magnitude higher than in average nuclear DNA [1], and mutant fractions in the order of one per 10,000 are not unheard of [3]. In other words, one can expect to find one mutation in approximately a dozen sequencing reactions. This price appears to be very attractive, and multiple laboratories use cloning in studies of somatic mutations in mtDNA [4-15]. Some recent studies invested heavily into sequencing of many millions of base pairs of clones in search of mutations [3,16-20]. Clone-by-clone mutational analysis is by no means limited to mtDNA, it can be and is successfully applied whenever one needs to resolve a relatively enriched mixture of mutations, which includes the many applications in toxicology where mutants can be enriched by positive selection in cultured cells [21].

## Post-PCR cloning: simplicity at the cost of PCR artifacts

Earlier studies involving clone-by-clone mutational analysis used direct cloning of cellular DNA in bacterial vectors [4,5], or used DNA from cloned mutated bacteria [2] or cells [21]. Recently, however, most researchers choose to clone PCR fragments, rather then the native cellular DNA. This post-PCR cloning procedure is attractive due to its relative simplicity. One does not need to purify mtDNA from nuclear DNA, and commercially available kits facilitate cloning of PCR fragments compared with the rather laborious direct cloning, although it is still necessary to make vector constructs, transfect bacteria and grow/analyze colonies. Furthermore, many experiments, including those performed in single cells or in specific small areas of the tissue, do not provide sufficient amounts of DNA for direct cloning. Finally, while feasible for the low-complexity genome such as mtDNA, direct cloning is much more difficult for nuclear DNA.

Despite its obvious advantages, the post-PCR cloning approach has serious drawbacks. PCR is known to generate artifacts, such as PCR errors and template rearrangements (jumping PCR), and to enrich some mutant alleles at the expense of others (allelic preference). Once the post-PCR mixture of DNA fragments is subject to cloning, PCR artifacts are also cloned and thus become legitimized and indistinguishable from the genuine mutations. If the frequency of cloned artifacts is comparable to or exceeds the expected fraction of genuine somatic mutations, then mutational analysis is compromised. The different sources of PCR artifacts and their impact on mutational analysis by post-PCR cloning will now be considered.

PCR errors do interfere with mutation analysis: the mtDNA example

It has been recognized for some time that DNA polymerases used in PCR are error prone and thus, PCR product contains random artificial mutations. Whether PCR errors represent a true problem in mutational analysis depends on how low a mutant fraction one intends to measure. The reports that used the (error-free) direct cloning approach allow estimation of the expected mutational rates in the mitochondrial genome, a likely candidate for post-PCR, cloning-based, mutational analysis. For human mtDNA, studies reported approximately three mutations per 10<sup>5</sup> nucleotides in peripheral lymphocytes [4], in leukemic cells of middle aged donors [22], and the retina of a 71-year-old donor [5]. The authors observed approximately 2.5 mutations per 10<sup>5</sup> nucleotides in a 40-year-old muscle [13]. A very large sequencing study reported approximately 2.6 mutations per 10<sup>5</sup> nucleotides in cultured human cells, and one mutation per 10<sup>5</sup> nucleotides in muscle and 0.4 mutations per 10<sup>5</sup> nucleotides in brain of 6-month-old mice [19]. In conclusion, to analyze somatic mutations in mtDNA, one has to be prepared to detect approximately one mutation per 10<sup>5</sup> bp.

Reported error rates of thermostable polymerases commonly used in PCR vary widely from  $2 \times 10^{-4}$  errors/bp/duplication for Taq polymerase to  $6 \times 10^{-7}$  errors/bp/duplication for pfu polymerase [23]. Assuming that a typical PCR amplification involved approximately 20 duplications (10<sup>6</sup>-fold amplification), these rates translate into a range of error fractions from 0.5 to 200 errors per 10<sup>5</sup> nucleotides. It therefore appears that even most high-fidelity polymerases are not quite suitable for post-PCR cloning since the fraction of errors is comparable to the in vivo mutant fraction. For example, Cantuti-Castelvetri and coworkers reported six to nine errors (depending on clonality assumptions) per 10<sup>5</sup> nucleotides with the HF2 highfidelity polymerase from Clontech after approximately 30 duplications [18]. Pfu polymerase was reported to provide better results – approximately 1.4 errors per 10<sup>5</sup> nucleotides after 25 cycles of PCR [3]. In conclusion, fractions of PCR errors observed in post-PCR cloning procedures are comparable to the fractions of in vivo mutations and thus may interfere with mutational analysis.

# Jumping PCR: a problem for preserving associations between mutations & for the analysis of recombinants

PCR amplification may involve template jumping [24], a condition where DNA polymerase switches from one template to another while maintaining synthesis of a continuous nascent DNA strand. The result is a composite molecule originating from two templates. Switching of templates has no net effect if the templates are identical or differ by one mutation. However, if the two templates differ by at least two mutations located on each side of the switching point, jumping produces a new type of molecule identical to a product of recombination between the two templates. In somatic mutational analysis, most molecules in a mixture are assumed to be wild type, and the probability of two mutant molecules meeting is low. If

2 Expert Rev. Mol. Diagn. 5(5), (2005)

two mutant molecules do meet and template jumping does create a double mutant molecule, then there is a high probability that the two mutants will be dissociated on the next encounter with a wild-type template. This logic seems to indicate that template switching is not a problem in mutational analysis, but in fact it is.

The jumping PCR artifact becomes important if there are more than one mutation per molecule within the DNA region under consideration. As the DNA fragments that are being scanned for mutations increase in length (it is not uncommon to scan the whole 16-kb mitochondrial genome [25,19]), the probability of finding a multiple-mutant genome becomes quite substantial. In this case, template switching may separate mutations that were originally on the same DNA molecule or, conversely, join originally disjoined mutations on the same DNA strand. This may create combinations of mutations that may not have existed in the original sample, but will be indistinguishable from the real ones upon cloning.

The information regarding mutation association may seem irrelevant to someone convinced that mutagenesis is a completely random process. However, preliminary data indicate that mutations are nonrandomly distributed between mtDNA molecules [KRAYTSBERG & COWORKERS, UNPUBLISHED DATA]. Certain mtDNA molecules appear to contain multiple mutations. This may indicate that there are mutator cells or mutator mitochondria within cells. Alternatively, certain combinations of molecules may have an advantage in propagation of the mtDNA molecules that harbor them. Information regarding such nonrandom associations would have been erased by jumping PCR.

Obviously, jumping artifact is unacceptable in any experiments studying DNA recombination, since products of jumping PCR, once they are cloned, are indistinguishable from genuine recombinant DNA molecules. A clear example of abundant artifactual recombinants created by precloning PCR has been reported recently [19].

# Allelic preference: a problem in quantification of deletion mutations

Allelic preference arises when templates with sequence variants present in a mixture of DNA fragments subject to PCR are amplified with unequal efficiencies. In a mixture of mutations, any mutation with an increased amplification efficiency will be over-represented in the post-PCR mixture. Allelic preference becomes particularly severe in the case of deletion mutations. Mutant DNA with large deletions may be amplified with drastically higher efficiency than the wild-type molecules due to its shorter length. Allelic preference is a long-standing problem in quantification of mtDNA deletions that are involved in mitochondrial disease and likely play a role in human aging [26]. Not only are deleted mtDNA better amplified than the wild type, the extent of allelic preference is highly sensitive to slight changes in PCR conditions, so not only do PCR-amplified mixtures deliver biased results, the comparison between different laboratories and even different PCR reactions is difficult.

Single-molecule PCR in mutational analysis:

## PCR without the artifacts

The authors have argued so far that although direct cloning in bacterial vectors is an excellent approach in mutational analysis, it is laborious and in many cases unfeasible. Post-PCR cloning is a much simpler approach but is subject to the various PCR artifacts. Therefore, the authors propose that single-molecule PCR (smPCR), an approach already used in a number of important applications, should be used in mutational analysis in place of post-PCR cloning. smPCR is even simpler than post-PCR cloning and does not suffer from many of its drawbacks.

It was demonstrated over a decade ago that PCR can be efficiently performed on a single DNA template [27]. This is achieved by performing multiple PCRs at limiting dilution, where DNA concentration is so low that many of the reactions (usually ~50%) by pure chance do not receive any template molecules at all and thus produce no PCR product. Under such conditions, the positive reactions are most likely to have been initiated by a single template molecule. Since its discovery, smPCR was used for mutational analysis of microsatellites [28] and is currently used for studies of recombination [29,30]. The method was reinvented several times under different names and used for construction of expression libraries [31] and for analysis of cancers for known mutations (digital PCR) [32,33]. Recently, smPCR was used to generate polonies – spots of PCR products originating from a single template that are immobilized in a thin gel layer on glass surface, similar to bacterial colonies in agar [34].

PCR amplification of a single molecule results in a clone of PCR fragments. Thus, using smPCR, one can bypass the cloning step in post-PCR cloning in mutational analysis, thereby simplifying the process. More importantly, it appears that when performed in the single-molecule mode, PCR amplification is immune to PCR errors, template jumping and allelic preference. This makes smPCR particularly suitable for mutational analysis of unknown somatic mutations, which, as shown above, suffers from all these artifacts. Therefore, it is a pity that smPCR has not yet established itself in the field of somatic mutation research. The methodological aspects of smPCR as applied to somatic mutation analysis have been described in a recent book chapter [13]. The reasons why smPCR is (or can be made) resistant to the various PCR artifacts are now discussed.

## smPCR reduces PCR error rate & permits filtering of the errors

One of the advantages of the digital data format is the availability of error-correction filtering, and digital output of smPCR is no exception. The principle of smPCR error correction is described in detail in FIGURE 1. Ideally, in PCR started from a single double-stranded DNA template, PCR errors cannot be present in more than 25% of the resulting PCR fragments (FIGURE 1). Indeed, an error can be introduced only during replication of an existing strand, and at the end of the first PCR cycle there will be four single strands and only one mutation (hence 25%). Thus, PCR errors can be easily identified and

www.future-drugs.com 3

discarded upon direct sequencing of the smPCR product as lowintensity subpeaks in the sequencing tracks. The genuine mutations are represented by 100% peaks in the sequencing chromatograms. This contrasts with post-PCR cloning, where PCR errors end up as 100% clones, just as genuine mutations do.

In reality, the initial single template of smPCR is not necessarily double stranded (even if one of the strands is not amplifiable, the PCR will meet the criteria of smPCR). This situation is likely if the amplified fragment is long and/or the fraction of damaged strands is high (low DNA quality). In this case, PCR

errors may represent up to 50% of the PCR product. Furthermore, original cellular templates may be copied with lower efficiency than the first PCR-derived DNA strands, and thus a PCR error introduced at the first duplication may have an additional advantage that will make the fraction of PCR fragments bearing this error even closer to 100%. Therefore, in the worst case scenario, a PCR-derived mutation introduced during the first cycle affects the whole smPCR clone. Even in this case, the expected error rate will be approximately 20-fold lower than that of the post-PCR cloning procedure with 20 duplications, because only one (the first) duplication, not all 20 of them, contributes to the number of errors.

# smPCR minimizes template jumping

The notion that smPCR is not subject to the jumping PCR artifact sounds almost as a tautology: apparently, there are no other molecules for PCR to (productively) jump to if only one original template molecule and its daughters are present in PCR. If PCR errors are disregarded, all daughter molecules are expected to be identical to the original, and thus jumping between daughter templates will not produce any new sequence. In fact, smPCR, as it is defined here, may contain additional nondaughter DNA molecules if these molecules are not amplifiable, for example, due to nicks or impassable base modifications of the DNA strands. The higher the probability of an impassable lesion in DNA (this probability increases with increasing length of PCR fragments and/or decreasing DNA quality), the larger the number of these additional nontemplate molecules will be present in smPCR. One can imagine that switching of DNA synthesis to an unamplifiable template may result in an amplifiable recombinant molecule if the switching occurred after the impassable lesion in the unamplifiable template. Even though jumping by this mechanism

can potentially occur, smPCR conditions




Figure 1. Rejection of PCR errors in smPCR. For the sake of illustration, the mutation mixture to be analyzed is represented by one mutant (double line with purple stars) and one wild-type molecule. A real sample contains many different mutants and many wild-type molecules. In this example, polymerase introduces approximately one error per two replications of the fragment under study. If a full 16-kb mtDNA is being amplified, this implies a reasonable error rate of ~3 x 10<sup>-5</sup> errors per bp per duplication. Polymerase introduces errors (colored stars) into the nascent strands to form mismatches (single stars) that are converted into double-stranded mutation (double stars) in the following PCR cycle. Although errors are introduced in the same way in conventional PCR and in smPCR, their fate is different. The distribution of mutations among individual smPCRs contains the information whether the mutation was present in the mixture prior to PCR onset. This information is lost in the post-PCR cloning approach. mtDNA: Mitochondrial DNA; smPCR: Single-molecule PCR.

4 Expert Rev. Mol. Diagn. 5(5), (2005) are certainly most appropriate to minimize template jumping. Jumping is a bimolecular process with respect to DNA concentration and is expected to be efficiently suppressed at low DNA concentrations such as those used in smPCR. Nevertheless, the absence of jumping in smPCR should be accounted for by the use of appropriate controls [30].

## smPCR neutralizes allelic preference

Allelic preference is caused by the different amplification efficiency of sequence variants. If a particular mutant template confers a higher amplification efficiency (compared with the wild type), then, in a mixture of mutant and wild-type DNA subject to PCR, the share of this mutant will increase with each cycle, resulting in its over-representation. In smPCR, the templates are amplified in separate reactions in the singlemolecule mode, and, naturally, more efficient templates will amplify faster and produce more abundant PCR product, while less efficient templates will yield fainter bands. Fortunately, this is not a problem for quantification, as in smPCR one considers only positive and negative reactions, while the quantity of the PCR product is not taken into consideration. However, it is important to set PCR conditions in such a way that even the least efficient template is amplified sufficiently to be reliably detected. In the most important and most severe case of allelic preference, the deletion mutations, the slowest variant is the wild type, which is the longest and thus most difficult species to amplify, and thus it is easy to make sure that the amplification conditions are appropriate by making sure that wild type is efficiently amplified. FIGURE 2 presents an example of how allelic preference is neutralized in case of mtDNA deletions.

## Methodological aspects of smPCR

Although PCR amplification of single molecules is feasible, it requires a more scrupulous approach than conventional PCR from a large number of template molecules. The main obstacle in single-molecule amplification is the competition between the desired PCR fragments and spurious PCR products, such as primer dimers. In general, amplification of single molecules becomes progressively more difficult as the length of the expected PCR fragment increases and, hence, PCR efficiency decreases. Some aspects of smPCR methodology for long fragments are described elsewhere [13]. A researcher wishing to use smPCR must be prepared to try several primer pairs and to use nested primers to increase PCR efficiency.

Another difficulty of smPCR is the higher possibility of contamination than in multicopy PCR. The contamination problem becomes more serious with progressively shorter PCR fragments, because shorter DNA fragments are more stable. The most likely scenario is the backward contamination of smPCR reactions with the end products of PCR. It is therefore important to use contamination precautions such as clean rooms and hoods to prepare DNA and assemble PCR reactions [13].




Figure 2. Allelic preference is neutralized by smPCR: quantification of mtDNA deletions. The leftmost lane shows a conventional PCR reaction started from approximately 10<sup>4</sup> molecules of mtDNA. The DNA was isolated from human substantia nigra, a brain area known for high content of mtDNA deletions. In addition to the band corresponding to the full-length wild-type mtDNA (16 kb), there is a complex mixture of various deleted species. It is tempting to conclude from the relative band intensity that deleted species (bands below the wild type), especially the shorter ones, greatly outnumber the wild type in this sample. The results of smPCR of the same DNA sample (rest of the lanes, negative smPCR reactions are omitted) demonstrate that such a conclusion is incorrect. Most single-molecule reactions contain pure wild-type product, which is thus the predominant species in the sample. The apparent bias in favor of the shorter deleted species was also eliminated in smPCR.

mtDNA: Mitochondrial DNA; smPCR: Single-molecule PCR.

## Expert commentary & five-year view

There has been a recent revival of interest in measuring unknown somatic mutations in a given DNA locus. mtDNA has been under particularly intense investigation, partly due to a number of reports that certain mutations in mtDNA accumulate in the aging tissues to very high levels, such that direct involvement of these mutations in the aging process may be suspected (e.g., see [17]). This trend is likely to increase thanks to the recent high-profile publication in Nature regarding the relationship between accelerated somatic mtDNA mutagenesis and aging phenotypes in transgenic mice [16]. The measurements of mutant fractions and the types of mutations are very important as they are used to determine whether mtDNA mutations can be of physiologic importance. The low abundance of these mutations was the most powerful argument against the involvement of mtDNA mutations in the aging process. Recent reports of high fractions of mtDNA mutations have started to reverse this argument. Therefore, the adequacy of the quantification approach is of crucial importance.

Currently, post-PCR cloning and subsequent mutational analysis of the clones is the predominant method used in quantification of mtDNA mutations. As argued in this review, this approach is prone to PCR errors. Interestingly, available data appear to indicate that mutant fractions as measured by direct cloning are indeed much lower than those measured by

www.future-drugs.com 5

post-PCR cloning. For example, mtDNA mutations in the brain of 6-month-old mice were estimated at 0.4 mutations per  $10^5$  nucleotides by direct cloning [19], while post-PCR cloning yielded 23 mutations per  $10^5$  nucleotides in 6-month-old rats [15]. It appears unlikely that this almost 2 orders of magnitude difference can be explained by the difference between the rat and the mouse. It is hoped that in the coming years, the inherent deficits of post-PCR cloning will receive more attention than previously, and it will be gradually

replaced by smPCR, which is simpler and less prone to artifacts. This will hopefully help to answer some long-standing questions about the predominant sources and importance of somatic mutation, and particularly the involvement of somatic mutations in mtDNA in the aging process.

## Acknowledgements

This work has been supported in part by grants ES11343 and AG19787 from the National Institutes of Health (NIH).

## Key issues

- Studies of mutational spectra involve analysis of complex mixtures of mutant DNA species with each type of mutant present at very low fractions.
- An efficient approach to such analysis is based on massive cloning of individual DNA molecules and subsequent identification of mutants in cloned DNA.
- In most studies, PCR amplification precedes cloning of mutant DNA. This may result in PCR-based artifacts:
  - Errors of the thermostable DNA polymerase are cloned and cannot be distinguished from genuine mutations.
  - Jumping PCR creates composite DNA molecules and thus mutant combinations that may not have existed in the original DNA.
  - Allelic preference can distort the relative abundancies of different mutations in the spectra.
- Single-molecule PCR, as a substitute of cloning, promises to alleviate the drawbacks of the post-PCR cloning approach. In addition, single-molecule PCR is simpler, faster and cheaper.

### References

Papers of special note have been highlighted as:
• of interest

•• of considerable interest

13798-13803 (1997).

- Khrapko K, Coller HA, Andre PC, Li XC, Hanekamp JS, Thilly WG. Mitochondrial mutational spectra in human cells and tissues. *Proc. Natl Acad. Sci. USA* 94(25).
- 2 Coulondre C, Miller JH. Genetic studies of the lac repressor. IV. Mutagenic specificity in the lacI gene of *Escherichia coli. J. Mol. Biol.* 117(3), 577–606 (1977).
- 3 Smigrodzki R, Parks J, Parker WD. High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol. Aging 25(10), 1273–1281 (2004).
- 4 Monnat R Jr, Loeb LA. Nucleotide sequence preservation of human mitochondrial DNA. *Proc. Natl Acad. Sci.* USA 82(9), 2895–2899 (1985).
- 5 Bodenteich A, Mitchell LG, Merril CR. A lifetime of retinal light exposure does not appear to increase mitochondrial mutations. *Gene* 108(2), 305–310 (1991).
- 6 Kovalenko SA, Tanaka M, Yoneda M, Iakovlev AF, Ozawa T. Accumulation of somatic nucleotide substitutions in mitochondrial DNA associated with the 3243 A-to-G tRNA(leu) (UUR) mutation in encephalomyopathy and cardiomyopathy. *Biochem. Biophys. Res.* Commun. 222(2), 201–207 (1996).

- Jazin EE, Cavelier L, Eriksson I, Oreland L, Gyllensten U. Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. *Proc. Natl Acad. Sci. USA* 93(22), 12382–12387 (1996).
- Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. *Science* 286(5440), 774–779 (1999).
- 9 Zhang D, Mott JL, Chang SW, Denniger G, Feng Z, Zassenhaus HP. Construction of transgenic mice with tissue-specific acceleration of mitochondrial DNA mutagenesis. *Genomics* 69(2), 151–161 (2000).
- Simon DK, Lin MT, Ahn CH et al. Low mutational burden of individual acquired mitochondrial DNA mutations in brain. Genomics 73(1), 113–116 (2001).
- 11 Khaidakov M, Heflich RH, Manjanatha MG, Myers MB, Aidoo A. Accumulation of point mutations in mitochondrial DNA of aging mice. *Mutat. Res.* 526(1–2), 1–7 (2003).
- 12 Del Bo R, Crimi M, Sciacco M et al. High mutational burden in the mtDNA control region from aged muscles: a single-fiber study. Neurobiol. Aging 24(6), 829–838 (2003).

- 13 Kraytsberg Y, Nekhaeva E, Chang C, Ebralidse K, Khrapko K. Analysis of somatic mutations via long-distance single molecule PCR. In: *DNA* Amplification: Current Technologies and Applications. Demidov VV, Broude NE (Eds), Horizon Bioscience, Norfolk, UK (2004).
- Description of the methodological aspects of single-molecule PCR (smPCR), with the emphasis on amplification of long DNA fragments.
- 14 Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. *Proc. Natl Acad. Sci. USA* 101(29), 10726–10731 (2004).
- 15 Khaidakov M, Chavannes-Turesky N, Cooney CA et al. Contribution of de novo point mutations to the overall mutational burden in mitochondrial DNA of adult rats. Exp. Gerontol. 40(5), 396–402 (2005).
- Trifunovic A, Wredenberg A, Falkenberg M et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429(6990), 417–423 (2004).
- 17 Simon DK, Lin MT, Zheng L et al. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol. Aging 25(1), 71–81 (2004).

**6** Expert Rev. Mol. Diagn. 5(5), (2005)

- 18 Cantuti-Castelvetri I, Lin MT, Zheng K et al. Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol. Aging (2005) (In Press).
- 19 Sato A, Nakada K, Akimoto M et al. Rare creation of recombinant mtDNA haplotypes in mammalian tissues. Proc. Natl Acad. Sci. USA 102(17), 6057–6062 (2005).
- Parker WD Jr, Parks JK. Mitochondrial ND5 mutations in idiopathic Parkinson's disease. *Biochem. Biophys. Res. Commun.* 326(3), 667–669 (2005).
- Albertini RJ. HPRT mutations in humans: biomarkers for mechanistic studies. *Mutat. Res.* 489(1), 1–16 (2001).
- 22 Monnat R Jr, Maxwell CL, Loeb LA. Nucleotide sequence preservation of human leukemic mitochondrial DNA. *Cancer Res.* 45(4), 1809–1814 (1985b).
- 23 Pavlov AR, Pavlova NV, Kozyavkin SA, Slesarev AI. Recent developments in the optimization of thermostable DNA polymerases for efficient applications. *Trends Biotechnol.* 22(5), 253–260 (2004).
- Comprehensive review of fidelity and other properties of thermostable polymerases.
- Paabo S, Irwin DM, Wilson AC. DNA damage promotes jumping between templates during enzymatic amplification. J. Biol. Chem. 265(8), 4718–4721 (1990).

- Taylor RW, Barron MJ, Borthwick GM et al. Mitochondrial DNA mutations in human colonic crypt stem cells. J. Clin. Invest. 112(9), 1351–1360 (2003).
- Kajander OA, Kunnas TA, Perola M, Lehtinen SK, Karhunen PJ, Jacobs HT. Long-extension PCR to detect deleted mitochondrial DNA molecules is compromized by technical artefacts. *Biochem. Biophys. Res. Commun.* 254(2), 507–514 (1999a).
- 27 Jeffreys AJ, Wilson V, Neumann R, Keyte J. Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells. *Nucleic Acids Res.* 16(23), 10953–10971 (1988).
- Jeffreys AJ, Neumann R, Wilson V. Repeat unit sequence variation in minisatellites: a novel source of DNA polymorphism for studying variation and mutation by single molecule analysis. *Cell* 60(3), 473–485 (1990).
- First paper on smPCR.
- 29 Yauk CL, Bois PR, Jeffreys AJ. Highresolution sperm typing of meiotic recombination in the mouse MHC Eβ gene. EMBO J. 22(6), 1389–1397 (2003).
- 30 Kraytsberg Y, Schwartz M, Brown TA et al. Recombination of human mitochondrial DNA. Science 304(5673), 981 (2004).
- 31 Lukyanov KA, Matz MV, Bogdanova EA, Gurskaya NG, Lukyanov SA. Molecule by molecule PCR amplification of complex

- DNA mixtures for direct sequencing: an approach to *in vitro* cloning. *Nucleic Acids Res.* 24(11), 2194–2195 (1996).
- 32 Vogelstein B, Kinzler KW. Digital PCR. Proc. Natl Acad. Sci. USA 96(16), 9236–9241 (1999).
- 33 Pohl G, Shih Ie M. Principle and applications of digital PCR. Expert Rev. Mol. Diagn. 4(1), 41–47 (2004).
- Recent review on the principles and applications of digital PCR.
- Mitra RD, Butty VL, Shendure J, Williams BR, Housman DE, Church GM. Digital genotyping and haplotyping with polymerase colonies. *Proc. Natl Acad. Sci. USA* 100(10), 5926–5931 (2003).
- •• Description of solid-state smPCR, resulting in the formation of polonies colony-like spots of PCR products.

## Affiliations

- Yevgenya Kraytsberg, MD
   Beth Israel Deaconess Medical Center &
  Harvard Medical School, 21–27 Burlington
  Avenue, Boston MA 02215, USA
  Tel.: PHONE
  Fax: FAX
  EMAIL
- Konstantin Khrapko, PhD
   Beth Israel Deaconess Medical Center &
  Harvard Medical School, 21–27 Burlington
  Avenue, Boston MA 02215, USA
  Tel.: PHONE
  Fax: FAX
  khrapko@hms.harvard.edu

www.future-drugs.com 7